Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel's Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

CAMBRIDGE, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated biomarker data from the BEACON Phase 1/2 clinical trial of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD) at the European Hematology Association 2026 Congress (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden. Risto-cel is an investigational autologous cell therapy with a potential best-in-class profile for the treatment of SCD.